Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

DAPAGLIFLOZIN for Obesity: Side Effects & Safety Data

Lose Weight Fast — The 21-Day Smoothie Diet

36 fat-burning recipes + shopping lists. Results in the first week.

Get the Program

There are 8 adverse event reports in the FDA FAERS database where DAPAGLIFLOZIN was used for Obesity.

Most Reported Side Effects for DAPAGLIFLOZIN

Side Effect Reports % Deaths Hosp.
Death 2,775 13.0% 2,774 52
Diabetic ketoacidosis 1,773 8.3% 61 1,154
Acute kidney injury 982 4.6% 67 768
Off label use 891 4.2% 28 310
Nausea 884 4.1% 20 363
Dehydration 860 4.0% 67 451
Vomiting 838 3.9% 27 419
Dizziness 817 3.8% 30 293
Ketoacidosis 803 3.8% 30 471
Fatigue 785 3.7% 8 227
Diarrhoea 769 3.6% 32 317
Dyspnoea 760 3.6% 21 328
Malaise 737 3.5% 30 308
Weight decreased 727 3.4% 23 231
Blood glucose increased 699 3.3% 12 247

Other Indications for DAPAGLIFLOZIN

Type 2 diabetes mellitus (5,444) Diabetes mellitus (3,347) Product used for unknown indication (1,534) Cardiac failure (1,332) Chronic kidney disease (585) Ill-defined disorder (556) Cardiac failure chronic (498) Type 1 diabetes mellitus (308) Blood glucose increased (145) Blood glucose abnormal (127)

Other Drugs Used for Obesity

SEMAGLUTIDE (2,586) LIRAGLUTIDE (1,090) BUPROPION\NALTREXONE (726) TIRZEPATIDE (700) ORLISTAT (163) PHENTERMINE (127) DULAGLUTIDE (109) METFORMIN (100) PHENTERMINE\TOPIRAMATE (86) TOPIRAMATE (86)

Related Pages

DAPAGLIFLOZIN Full Profile All Obesity Drugs DAPAGLIFLOZIN Demographics DAPAGLIFLOZIN Timeline